Sugi Predict

Sugi Predict / Compounds / SCHEMBL4091190

SCHEMBL4091190

SCHEMBL4091190

O=C(O)CCNC(=O)c1ccc(C(CCc2cccc(Cl)c2)NC(=O)Nc2cccc(SC(F)(F)F)c2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TRPV1 Q8NER1 1/20 0.43
▸ GCGR P47871 4/20 0.41
▸ HSPH1 Q92598 1/20 0.41
▸ UBE2M P61081 1/20 0.40
▸ DCUN1D1 Q96GG9 1/20 0.40
▸ EPHX2 P34913 1/20 0.39
▸ DGAT1 O75907 1/20 0.39
▸ KMT2A Q03164 3/20 0.39
▸ MEN1 O00255 2/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ PPARG P37231 1/20 0.39
▸ PPARD Q03181 1/20 0.39
▸ PPARA Q07869 1/20 0.39
▸ NR1H4 Q96RI1 1/20 0.39
▸ GCG P01275 1/20 0.38
▸ HDAC8 Q9BY41 1/20 0.38
▸ ALDH1A1 P00352 2/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4081405 0.85 CASR (0.49) TRPV1GCGREPHX2SMN1; SMN2CASR
SCHEMBL4081876 0.84 TRPV1 (0.61) TRPV1GCGRCNR1ADCY6ADCY3
SCHEMBL4087375 0.81 AURKA (0.40) GCGREPHX2GCGADCY6ADCY3
SCHEMBL2663188 0.79 GCGR (0.50) TRPV1GCGRHSPH1DGAT1PPARG
SCHEMBL4086535 0.75 GCGR (0.38) GCGRUBE2MDCUN1D1EPHX2GCG
SCHEMBL4095200 0.74 GCGR (0.48) GCGRUBE2MDCUN1D1EPHX2GCG
SCHEMBL4092841 0.74 GCGR (0.46) GCGRGCGADCY6ADCY3ADCY9
SCHEMBL4086854 0.73 TRPV1 (0.60) TRPV1GCGRADCY6ADCY3ADCY9
SCHEMBL4081879 0.73 RAB9A (0.49) GCGREPHX2KMT2AMEN1NPC1
SCHEMBL4094036 0.72 GCGR (0.51) TRPV1GCGRGCGADCY6ADCY3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists NOVO NORDISK A/S (DK) 2009-06-04 — — US disclosed
EP-1183229-B1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK AS (DK) 2005-10-26 — — EP disclosed
US-20050203108-A1 Glucagon antagonists/inverse agonists PFIZER INC 2005-09-15 — — US disclosed
US-6875760-B2 Glucagon antagonists/inverse agonists NOVO NORDISK A/S (DK) 2005-04-05 — — US disclosed
US-20030220350-A1 Glucagon antagonists/inverse agonists PFIZER INC 2003-11-27 — — US disclosed
US-6503949-B1 Treating Type 2 diabetes, hyperglycemia, impaired glucose tolerance or obesity NORO NORDISK A/S (DK) 2003-01-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050203108-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR TRPV1 1930/4885GCGR 3/4885HSPH1 1754/4885
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists GLP1R, GPR119, GCGR TRPV1 1930/4885GCGR 3/4885HSPH1 1754/4885
US-20030220350-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR TRPV1 1930/4885GCGR 3/4885HSPH1 1754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.